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CARE DELIVERYoriginal
contribution
Patient-Centered Medical Homes in Community
Oncology Practices: Changes in Spending and
Care Quality Associated With the COME
HOME Experience
Teresa M. Waters, PhD1,2; Cameron M. Kaplan, PhD2; Ilana Graetz, PhD2; Mary M. Price, MA3; Laura A. Stevens4,5; and
Barbara L. McAneny, MD4,6,7
QUESTION ASKED: Given that the patient-centered
medical home model of health care delivery has
enjoyed widespread support among provider specialty
groups, could the Community Oncology Medical
Home (COME HOME) model be used to improve
quality of patient care, improve health outcomes, and/
or reduceMedicare spending during the first 6 months
of treatment of elderly oncology patients in community
oncology practices?
SUMMARY ANSWER: Compared with propensity score–
matched concurrent controls from similar geographic
areas, postintervention medical spending was reduced
by amodest but statistically significant 8.1% per patient.
Quality of care, as measured by number of emergency
department visits per patient, was also improved by a
statistically significant amount.
WHAT WE DID: We used difference-in-differences com-
parison to evaluate outcomes of elderly Medicare ben-
eficiaries diagnosed with breast, lung, colorectal,
lymphoma, thyroid, melanoma, or pancreatic cancer
between 2011 and 2015 who were served by COME
HOME practices before and after program imple-
mentation versus concurrent comparable beneficiaries,
using propensity score matching and regression
methods to adjust for clinical and sociodemographic
differences.
WHAT WE FOUND: Six-month medical spending was
reduced by a statistically significant $2,657 per
Medicare beneficiary, and emergency department
visits were reduced by 10.2 percentage points per
1,000 patients over the same time period. However,
other outcome indicators, including 6-month out-of-
pocket spending, inpatient and ambulatory care–
sensitive hospitalizations, readmissions, length of
stay, and evaluation and management visits, were
unchanged.
BIAS, CONFOUNDING FACTOR(S), REAL-LIFE IMPLICATIONS:
Statistical power for comparing study outcomes before
and after implementation of the COME HOME pro-
gramwas limited by practice size, number of Medicare
fee-for-service patients meeting study criteria, in-
ability to randomly assign practices or patients to
study conditions, and length of the study period.
Differential changes in unobserved patient case mix
could have contributed to our findings, but differences
in observed patient characteristics between COME
HOME participants and controls were not significant.
Although cost savings and care improvements were
related to implementation of the COME HOME model,
participating practices could have concurrently imple-
mented unrelated interventions to account for these
changes; however, during our site visits to these prac-
tices, we were not aware of any other major changes at
these sites. Finally, the results were not uniform across
the seven sites in the study.
Our results suggest potential for this model to offer cost
savings and care improvements more widely. Broader
evaluation is necessary to include other populations,
such as those with relapsing disease, who may also
benefit from the program.
CORRESPONDING AUTHOR
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abstract
PURPOSE We examined whether the Community Oncology Medical Home (COME HOME) program, a medical
home program implemented in seven community oncology practices, was associated with changes in spending
and care quality.
PATIENTS AND METHODSWe compared outcomes from elderly fee-for-service Medicare beneficiaries diagnosed
between 2011 and 2015 with breast, lung, colorectal, thyroid, or pancreatic cancer, lymphoma, or melanoma
and served by COME HOME practices before and after program implementation versus similar beneficiaries
served by other geographically proximate oncologists. Difference-in-differences analysis compared changes in
outcomes for COME HOME patients versus concurrent controls. Propensity score matching and regression
methods were adjusted for clinical and sociodemographic differences. Our primary outcome was 6-month
medical spending per beneficiary. Secondary outcomes included 6-month out-of-pocket spending, inpatient and
ambulatory care–sensitive hospitalizations, readmissions, length of stay, and emergency department and
evaluation and management visits.
RESULTS Before COME HOME, 6-month medical spending was $2,975 higher for the study group compared
with controls (95% CI, $1,635 to $4,315; P , .001) and increasing at a similar rate. After intervention, this
difference was reduced to $318 (95% CI,2$1,105 to $1,741; P = .661), a significant change of2$2,657 (95%
CI, 2$4,631 to 2$683; P = .008) or 8.1% savings relative to 6-month average spending ($32,866). COME
HOME was also associated with significantly reduced (10.2 %) emergency department visits per 1,000 patients
per 6-month period (P = .024). There were no statistically significant differences in other outcomes.
CONCLUSION COME HOME was associated with reduced Medicare spending and improved emergency de-
partment use. The patient-centered medical home model holds promise for oncology practices, but im-
provements were not uniform.
J Oncol Pract 15:e56-e64. © 2018 by American Society of Clinical Oncology
INTRODUCTION
The patient-centered medical home (PCMH) model of
health care delivery has enjoyed widespread support
across multiple payers and provider specialty groups.
PCMH combines concepts of primary care (eg, per-
sonal physician, comprehensive care) with a com-
mitment to systematic improvements in population
health, using technology, tracking, and communica-
tion. The PCMH framework was developed by
the American College of Physicians, the American
Academy of Family Physicians, the American Acad-
emy of Pediatrics, and the American Osteopathic
Association1 and subsequently endorsed by the
American Medical Association and multiple medical
specialty associations.2 PCMH was also featured
prominently in the Patient Protection and Affordable
Care Act, establishing the Center for Medicare and
Medicaid Innovation (CMMI) and piloting a broad
range of payment and practice reforms.3
There is some evidence that the PCMH model of care
can improve patient care quality and health outcomes
and reduce health care utilization, although results
have been somewhat mixed and derived mostly in
primary care settings, with effect sizes generally be-
ing small to moderate.4 In primary care settings,
PCMH has been associated with modest improve-
ments in patient satisfaction and perceived care
coordination.5,6 Current evidence also suggests that
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PCMH is associated with modest reductions in emergency
department (ED) visits, particularly for older adults, and
reductions in ambulatory care–sensitive hospital admis-
sions. There is still limited evidence on the effect of PCMH
on overall hospital admission or costs of care.7
As payers and providers pursue new payment and delivery
models in specialty care, seeking to increase value by im-
proving outcomes and quality and lowering costs, there has
been growing interest in the PCMHmodel. To date, however,
adaptation of the model to specialty providers has been
relatively limited, and evidence of its effect is lacking. On-
cology medical homes are of particular interest as a result of
care fragmentation, significant practice variation, and high
costs of care.8 One medical oncology practice achieving
National Committee for Quality Assurance level III certification
as a primary care PCMH reported significant reductions in
both ED and inpatient admissions.9 A UnitedHealthcare
bundled payments pilot in five oncology practices also re-
ported significantly reduced inpatient and ED use and cost
savings.10 There is some evidence to suggest that PCMHmay
be particularly well suited to patients with high costs, complex
care needs, and multiple care transitions.11,12 In addition, the
benefits of PCMH are likely to accrue more rapidly in the
oncology patient population because treatment and symptom
management occur in a relatively compressed time frame
relative to other chronic conditions.13
In 2016, Medicare partnered with 16 commercial payers to
launch the Oncology Care Model (OCM) program, selecting
190 oncology practices across the country to participate in
an alternative payment model that emphasizes PCMH
principles.14-16 We report on outcomes associated with a
prequel to the OCM program, a Centers for Medicare and
Medicaid Services (CMS)–funded innovation program
guided by PCMH principles, called the Community On-
cology Medical Home (COME HOME) program, that was
implemented in seven community oncology practices be-
tween 2013 and 2015. To our knowledge, this study
represents the first outcome evaluation of a specialty
medical home in medical oncology.
PATIENTS AND METHODS
Setting
COME HOME was implemented in seven community on-
cology practices located in seven metropolitan areas in six
different states between September 2012 and June 2015.8
These practices were selected for inclusion after meeting
initial screening criteria related to minimum number of
Medicare patients, meaningful use of electronic health
records, and noncompeting locations and facilities, and
after agreeing to implement the program and support
study-related monitoring and reporting.
Program Design
The COME HOME model built on the original PCMH
framework1 to ensure safe, efficient, and high-quality care.
Each COMEHOME program offered patients a triage phone
line (open 24 hours a day, 7 days a week) that was staffed
during regular hours by first responders (trained telephone
operators) and nurses and during after regular business
hours by physicians with access to the patients’ electronic
health records. Practices offered same-day appoint-
ments and evening and weekend hours to ensure patient
access and early intervention for developing problems.
When possible, direct hospital admitting by on-call on-
cologists was also used to limit patient hand-offs; however,
some health plans required use of a hospitalist, and this has
become more prevalent over time. On-site or near-site
laboratory, pharmacy, and imaging capabilities allowed
practices to diagnose and treat many emerging condi-
tions rapidly.
Structured triage pathways offered through a Web-enabled
decision support tool were used by first responders and
triage nurses to ensure that all patients received a level of
care appropriate to their situation. Practice physicians
worked collaboratively to develop clinical pathways for
diagnosis and treatment of the seven cancer types included
in the study (breast, lung, colorectal, lymphoma, thyroid,
melanoma, or pancreatic cancer), using the National
Comprehensive Cancer Network guidelines as a starting
point and incorporating biomarker testing and imaging.
Implementation of pathways was driven by computerized
physician order entry and dynamically tracked on the basis
of patient progress. Additional program details are pub-
lished elsewhere.8,17
Study Design and Outcomes
To evaluate the effect of the COME HOME program on
health care spending and utilization-based quality-of-care
measures, we conducted a prepost, propensity score–
matched (PSM) retrospective cohort study (Fig 1). Although
the COMEHOME programwas open to all oncology patients
at most practice sites, we limited our outcomes evaluation
to Medicare patients with one of seven main cancer types
(breast, lung, colorectal, lymphoma, thyroid, melanoma,
or pancreatic cancer). Because of programmatic support
from CMS, these patients were of particular interest, and
their claims were available to us as part of program
monitoring.
All seven oncology practices were asked to identify their
newly diagnosed Medicare patients for possible study in-
clusion. Patients in relapse were excluded to increase
comparability of patients. Claims-based criteria were used
to refine the study samples to facilitate construction of a
claims-based comparison group. Practices identified 4,932
Medicare patients receiving COME HOME services be-
tween 2013 and 2015. From this population, we excluded
patients who did not meet claims-based criteria for being
newly diagnosed or having newly relapsed disease, defined
as one inpatient or two outpatient claims with an In-
ternational Classification of Diseases, Ninth Revision, code
Journal of Oncology Practice e57
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of a specific cancer and eliminating individuals with a
cancer claim in the prior 12 months; patients with a di-
agnosis date before practice implementation of the COME
HOME program; patients with less than 6 months of
postdiagnosis follow-up in claims; and patients with no
evaluation and management (EM) claim with a COME
HOME provider in the 6 months after diagnosis (Medicare
Advantage beneficiaries).
A comparison group of preintervention patients who received
care at the seven practices was identified using Medicare fee-
for-service (FFS) claims. Similar to the postintervention
group, we eliminated beneficiaries who had no cancer claim
in the study period, those with less than 6 months of post-
diagnosis follow-up in claims, and those with no EM claim
with a COMEHOME provider in the 6months after diagnosis.
For our preintervention sample, we also excluded benefi-
ciaries with a 2011 diagnosis because these individuals did
not have a full year of data for calculating comorbidity scores.
Our final sample sizes were 2,578 patients at COME HOME
practices for the preintervention period and 2,290 COME
HOME patients at COME HOME practices for the post-
intervention period (Fig 2).
Using Medicare claims, we identified a pool of potential
control patients that include all Medicare enrollees with a
newly diagnosed or newly relapsed cancer diagnosis who
saw a non–COME HOME oncologist in the 6 months after
diagnosis in the same states (Florida, Georgia, Maine, New
Mexico, Ohio, and Texas). Patients with newly diagnosed or
newly relapsed cancer were identified using one inpatient
or two outpatient claims with an International Classification
of Diseases, Ninth Revision, code of a specific cancer;
individuals with a cancer claim in the prior 12 months were
eliminated. The same exclusion criteria applied to the
COME HOME samples (Fig 2) were used to refine the pool
of potential controls. To ensure best possible matches
between intervention and control groups, all control pa-
tients served as possible matches for the postintervention
sample, whereas all control patients diagnosed before
2014 served as possible matches for the preintervention
sample. Thus, it is possible that some control patients were
matched to patients in both the pre- and postintervention
samples (n = 301).
Nearest neighbor PSM method was used to match three
control patients to each COME HOME patient from the pre-
and postintervention samples for final analyses. Our PSM
models matched on diagnosis month and year, age at
diagnosis, sex, race, concurrent hierarchical classification
category score, treatment (surgery, chemotherapy, and/or
radiation), metastatic cancer, years of Medicare enroll-
ment, county-level socioeconomic variables (median family
income, education, and urban indicator), state, death in
follow-up period, original reason for Medicare entitlement
(age, disability or end-stage renal disease, or both), and
dual eligibility (Medicare and Medicaid) indicator.
This project was viewed and approved by the University of
Tennessee Health Science Center Institutional Review
Board before any investigation and in accordance with
assurances filed with and approved by the US Department
of Health and Human Services. Because our evaluation
constituted evaluation of a public program, informed
consent was not required.
Statistical Analysis
Changes between preintervention and postintervention
periods in the intervention and control patients were
compared using a PSM difference-in-differences analysis.
After matching, we calculated the difference in study
outcomes between the COME HOME patient and the mean
of the three matched controls. We then adjusted for
practice site–specific differences in outcome levels using a
linear regression, regressing the calculated difference on
an indicator for the postintervention period and practice
site indicators. The coefficient on the postintervention
period from this regression is the difference-in-difference
estimate. To show the pre- and postintervention differences
between COME HOME patients and controls, we calcu-
lated the average adjusted mean differences by inserting
the mean values of the practice site indicators (ie, the
Staggered program implementation
at seven sites*
Preimplementation patients Postimplementation patients
2012 2013 2014 2015
January 1, 2012 June 20, 2015
FIG 1. Community Oncology Medi-
cal Home (COME HOME) model
program and evaluation timeline. (*)
Staggered implementation of COME
HOME program; beta site began
enrollment in September of 2013,
three additional practices began
enrollment in December of 2013,
and the final three practices began
enrollment in March of 2014.
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proportion of patients in each practice) in our regression
equation. We report two-sided P values with a significance
threshold of P , .05. All analyses were conducted with
STATA version 13.1 (STATA, College Station, TX).
RESULTS
During the 21 months of the COME HOME program, seven
participating clinics provided medical home services to 4,932
Medicare patients (Fig 2). After exclusions, our analysis fo-
cused on 2,290 eligible patients with breast, lung, colorectal,
thyroid, or pancreatic cancer, lymphoma, or melanoma who
received services and 2,578 similar, preintervention patients
who received care at these participating clinics, identified
through claims review. PSM matching yielded 7,734 pre-
intervention patients and 6,870 postintervention controls
with similar characteristics at other oncology practices in
the same geographic areas (Table 1).
The changes in patient health care spending and utili-
zation comparing COME HOME practice patients and
controls before and after the intervention are listed in
Table 2. Before implementation of the COME HOME
model, 6-month, per-beneficiary Medicare spending for
the study group was $2,975 higher than for the control
group (95% CI, $1,635 to $4,315; P , .001) and in-
creasing at a similar rate. In the postintervention period,
this difference was reduced to $318 (95% CI,2$1,105 to
$1,741; P = .661), constituting a significant change
of2$2,657 (95% CI,2$4,631 to2$683; P = .008) or an
8.1% savings relative to the 6-month mean baseline
spending of $32,866 for the treatment group. We also
found that COME HOME was associated with a significant
reduction (10.2 %) in ED visits per 1,000 patients per
6-month period after introduction of the program (P =
.024). Although the difference-in-differences point es-
timates for out-of-pocket costs, inpatient and ACS admis-
sions, length of stay, and inpatient days were negative, we
were unable to detect statistically significant effects in the
overall sample (Table 2). We expected to find increased EM
visits and decreased hospital readmissions, consistent with
the model of care, but were also unable to detect these
changes.
DISCUSSION
Although the PCMH model of care delivery has enjoyed
widespread support, there is relatively modest evidence
that it has a measurable effect on health outcomes, quality
of care, and cost savings.18,19 The evidence of effect is even
more limited for medical homes adapted to specialty care,
although programs addressing the needs of individuals
with severe mental illness20 and high-risk pediatric
populations11,21 have yielded promising results. Our find-
ings are consistent with two previous, but more limited
Preintervention Sample
Patients with claim confirmed
cancer dx between 2012 and 2014,
6 months of TM A and B after
diagnosis (or death), and an
EM visit with a COME HOME
provider in 6 months after
cancer dx
Eligible patients that could be
matched to a control patient
Excluded (n = 729,230)
No Medicare
  cancer claim
(n = 608)
(n = 42,384)
(n = 322,875)
(n = 363,363)2011 diagnosis
< 6 months of
  follow-up
No EM with a
COME HOME
provider in 6
months after
diagnosis
Postintervention Sample
Medicare patients identified by
one of seven practices as
receiving services under
COME HOME program
between 2013 and 2015
Patients with claim confirmed
cancer dx after practice start
date, 6 months of TM A and B
after diagnosis (or death), and
an EM visit with a COME
HOME provider in 6 months
after cancer dx
Eligible patients that could be
matched to a control patient
Excluded
Diagnosis date
  before practice
  start date
< 6 months of
  follow-up
No EM with a
  COME HOME
  provider
 (n = 2,604)
No Medicare
  cancer claim
(n = 552)
(n = 222)
(n = 297)
(n = 1,533)
(n = 2,290)
(n = 2,328)
(n = 4,932)
(n = 2,578)
(n = 2,591)
Medicare patients in the
claims files that were not
also in the postintervention
study group (n = 731,821)
FIG 2. Identification of pre- and postintervention
study samples and inclusion and exclusion
criteria. COME HOME, Community Oncology
Medical Home; dx, diagnosis; EM, evaluation
and management; TM A and B, enrolled in
traditional Medicare with both parts A and B.
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studies of oncology medical homes, which found cost
savings associated with reduced ED visits and inpatient
admissions.12,13 A CMS-funded external evaluation of the
COME HOME program, using a different methodology, also
found significant reductions in ED visits and total costs of
care.22,23
Why did we not see more effect of the program on outcomes
across the board?With the care fragmentation and high costs
of care that are characteristic of oncology care, somemay be
disappointed. We suggest that adaptation of the medical
home model to oncology care engenders some particularly
unique challenges. First, and perhaps most importantly,
each type of cancer is not one disease, but many, requiring
the clinical team to consider a myriad of diagnostic tests and
treatment options at multiple points along the patient’s
treatment journey. The sheer complexity of decision making
in oncology makes the concepts of best practices and
patient-centered care much more complicated and multi-
faceted. This complexity, combined with significant clinical
variation not under the control of the clinician, leads to wide
variation in treatment costs,24,25 which has several important
implications in the context of PCMH. It means that large
patient pools will be required to determine whether the
program is actually having an effect. Thus, it is possible that
our evaluation was still underpowered to detect the full effect
of the COME HOME program on study outcomes.
Second, the wide variation in treatment costs implies that
physician practices may have great difficulty bearing the
financial risk associated with oncology care. Many standard
models currently under consideration for primary care
specialties set financial targets for episodes of care.26 Al-
though these have demonstrated promising results, they
may place toomuch financial risk on oncologists. The OCM,
rolled out by CMS to 190 practices in 2016, tries to account
for this significant concern by limiting provider risk while still
incentivizing performance.14,15 Under OCM, physicians are
paid on a FFS basis and receive prospective Monthly
Enhanced Oncology Services payments; they are also eli-
gible for retrospective performance-based incentives that
focus on quality of care for higher volume cancers where
CMS believes that accurate benchmarks can be calculated.
Interestingly, providers who fail to meet utilization targets
during initial OCMprogram years will be eliminated from the
program; given the highly variable nature of costs in on-
cology care, at least some of the eliminated practices were
likely as efficient as some of the practices that remain in the
OCM program.
To understand whether per-patient cost savings generated
by COME HOME ($2,657) were significant in light of pro-
gram costs, we estimated per-patient program costs
($2,527) using CMMI support for the program
($17,432,432) and the number of unique patients served
(6,930; all patients, all payers, including Medicare FFS and
Advantage). Because these program costs may have been
artificially inflated as a result of the tracking and quarterly
reporting required by CMMI, we also calculated a practice-
only average program cost per patient ($1,823) by dividing
CMMI support for the seven community oncology practices
($12,633,771) by unique patients served (n = 6,930). The
resulting net savings ($130 to $834) were somewhat
modest relative to the average 6-month spending for this
population ($32,866; 0.4% to 2.54%). Although these
savings were modest relative to program costs, a sub-
sequent iteration of the COME HOME model has already
made model adjustments to boost efficiency by trimming
evening and weekend clinics to focus on peak use times,
updating information technology interfaces to improve
functionality and efficient patient management, and en-
hancing reporting through increased frequency and more
actionable formats.
TABLE 1. Characteristics of Study and Control Patients, Preintervention and Postintervention
Characteristic
Preintervention Postintervention
Study Patients
(n = 2,578)
Control Patients
(n = 7,734) P
Study Patients
(n = 2,290)
Control Patients
(n = 6,870) P
Mean age, years 72.6 72.6 .795 72.3 72.5 .254
Female sex, % 64.12 63.4 .508 66.72 66.49 .838
Race or ethnicity, % .985 .986
Black 5.31 5.34 6.29 6.39
Hispanic 3.14 3.3 4.45 4.43
White 89.49 89.29 86.46 86.26
Other 2.06 2.07 2.79 2.93
Cancer diagnosis, % .704 .964
Breast 34.33 34.43 39.74 39.68
Lung 29.33 30.22 26.55 26.1
Colorectal 17.34 16.47 16.33 16.49
Other 19.01 18.88 17.38 17.73
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Our findings have several implications for payment and
delivery reforms. Even in the absence of strong payment
incentives, community oncology practices were able to
implement PCMH infrastructure on a relatively aggressive
timeline in a manner that resulted in meaningful re-
ductions in Medicare expenditures per patient as well as
an overall reduction in ED visits. Our results also suggest
that the current nature of oncology diagnosis and treat-
ment yields highly variable cost structures that may im-
pede program evaluation and, potentially, payment
reforms. With our study sample (N = 19,472, including
2,290 COME HOME patients, 2,578 pre-intervention
patients at seven practices, and 14,604 controls), we
were able to detect statistically significant and, arguably,
clinically meaningful differences in total spending
($2,975) and ED visits per 1,000 patients (102 fewer
visits). Comparing point estimates and SEs for other study
outcomes, we estimate that sample size increases ranging
from 32% (inpatient days) to 290% (inpatient length of
stay) would be necessary to detect significant changes in
these areas. Alternatively, although our analyses of claims
data did not identify any homogeneous patient subgroups
in the data (eg, by tumor type), this could change with
better patient-specific data or new discoveries that alter
patterns of diagnosis and treatment. More homogeneous
subgroups would lower SEs and decrease required
sample sizes to detect differences or changes.
Our study had several limitations. Several factors limited
statistical power for comparing study outcomes before and
after implementation of the COMEHOMEprogram, including
practice size, number of Medicare FFS patients meeting
study criteria, inability to randomly assign practices or pa-
tients to study conditions, and length of the study period.
Differential changes in unobserved patient case mix could
have contributed to our findings, but differences in observed
patient characteristics between COME HOME participants
and controls were not significant. Although our results
suggest that cost savings and care improvements were re-
lated to implementation of the COME HOME model, par-
ticipating practices could have concurrently implemented
unrelated interventions to account for these changes;
however, during our site visits to these practices, we were not
aware of any other major changes at these sites.
Nevertheless, our study suggests that community oncology
practices were capable of making the organizational
changes necessary to support modest reductions (8.1%) in
spending for Medicare beneficiaries. Although imple-
mentation of the COME HOME model in other practices and
settings may differ, our results suggest potential for this
model to offer cost savings and care improvements more
widely, even in the absence of strong financial incentives.
Broader evaluation is necessary to include non-Medicare
populations, such as those with relapsing disease, who may
also benefit from the program.
TABLE 2. Differences in Patient Health Care Spending and Use: COMEHOME Practices ComparedWith Controls, Before and After Program Implementation
Outcome*
Preintervention
Patients†
Preintervention
Controls†
Preintervention
Difference
(95% CI)
Postintervention
Patients†
All COME HOME Practices: Patients and Controls
Postintervention
Controls†
Postintervention
Difference
(95% CI)
Difference in
Differences
(95% CI) P
Total spending, $ 35,786 32,866 2,975 (1,635 to 4,315) 19,563 19,183 318 (21,105 to 1,741) 22,657 (24,631 to 2683) .008
OOP costs, $ 4,965 4,644 332 (142 to 523) 3,040 2,867 160 (243 to 362) 2173 (2453 to 108) .227
ED visits per 1,000
patients, No.
906 817 89 (29 to 149) 769 781 213 (276 to 51) 2102 (2190 to 213) .024
Inpatient admissions
per 1,000 patients,
No.
643 633 7 (236 to 51) 640 664 222 (268 to 24) 229 (293 to 35) .375
Inpatient days per
1,000 patients, No.
3,642 3,510 130 (2190 to 440) 3,455 3,719 2260 (2590 to 80) 2380 (2850 to 80) .108
Readmissions per
1,000 patients,
No.‡
455 492 245 (2106 to 16) 452 462 21 (266 to 64) 44 (246 to 134) .342
Inpatient LOS, days‡ 8.69 8.79 20.17 (20.79 to 0.44) 8.29 8.78 20.42 (21.07 to 0.24) 20.25 (21.15 to 0.66) .597
EM visits per 1,000
patients, No.
10,799 9,647 1,188 (892 to 1,484) 11,877 10,475 1,361 (1,047 to 1,675) 173 (2262 to 609) .435
ACS admissions per
1,000 patients, No.
54 51 3 (28 to 13) 50 55 25 (216 to 7) 27 (223 to 9) .373
Abbreviations: ACS, ambulatory care sensitive; COME HOME, Community Oncology Medical Home; ED, emergency department; EM, evaluation
and management; LOS, length of stay; OOP, out of pocket.
*Per 6-month observation period.
†Not adjusted for practice-level controls.
‡Among patients and controls with at least one hospitalization.
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